Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Deals

Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology

Fineline Cube Oct 9, 2023

The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...

Company Deals

Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million

Fineline Cube Oct 9, 2023

Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...

Company Drug

Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4

Fineline Cube Oct 9, 2023

Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...

Company Drug

FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment

Fineline Cube Oct 9, 2023

The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...

Company Deals

Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas

Fineline Cube Oct 9, 2023

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...

Policy / Regulatory

Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030

Fineline Cube Oct 9, 2023

The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...

Company Deals

ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform

Fineline Cube Oct 9, 2023

China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with...

Company Deals

Alphamab Oncology Enters Licensing Agreement with Grand Life Sciences for KN057 in Greater China

Fineline Cube Oct 9, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a licensing agreement with fellow Chinese firm Grand...

Company Deals

Chongqing Zhifei Partners with GSK for Shingrix Distribution in China

Fineline Cube Oct 9, 2023

China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and...

Company Deals

Mabwell Bioscience Enters Licensing Agreement with Laboratorios Legrand for Biosimilars in Colombia and Ecuador

Fineline Cube Oct 9, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a strategic licensing agreement with...

Company Drug

Innovent Biologics Doses First Patient in Phase 3 Study of IBI302 for Neovascular AMD

Fineline Cube Oct 9, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient with neovascular age-related...

Policy / Regulatory

NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management

Fineline Cube Oct 9, 2023

The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...

Company Medical Device

Sino Medical Sciences’ HT Supreme Stent System Included in French Reimbursement List

Fineline Cube Oct 9, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading medical device company based in China,...

Company Drug

HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan

Fineline Cube Oct 9, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has...

Company Drug

Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra

Fineline Cube Oct 9, 2023

Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...

Company Drug

Sichuan Biokin’s IZalontamab Gets US FDA Greenlight for NSCLC Clinical Study

Fineline Cube Oct 9, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

Innovent Biologics Withdraws Parsaclisib Filing in China, Halts Development

Fineline Cube Oct 9, 2023

Innovent Biologics Inc., a leading China-based biotech company (HKG: 1801), has announced the voluntary withdrawal...

Company Deals Drug

Jiangsu Hengrui Licenses Pyrotinib to Dr. Reddy’s for Indian Market

Fineline Cube Oct 8, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has entered into a licensing agreement with...

Policy / Regulatory

Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative

Fineline Cube Oct 8, 2023

The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial...

Company Deals

Sanofi Enters Collaboration with Teva for IBD Drug TEV’574 Development

Fineline Cube Oct 8, 2023

Sanofi (NASDAQ: SNY) has entered into a collaboration agreement with Teva (NYSE: TEVA) for the...

Posts pagination

1 … 498 499 500 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.